Which second-line treatment regimen should be used following relapse of platinum-sensitive ovarian cancer?

被引：0
|
作者：
Pecorelli, Sergio
Odicino, Franco
机构：
[1] Univ Brescia, Dept Obstet & Gynecol, Div Gynecol Oncol, I-25123 Brescia, Italy
[2] Univ Brescia, Dept Obstet & Gynecol, Brescia, Italy
来源：
NATURE CLINICAL PRACTICE ONCOLOGY | 2007年 / 4卷 / 06期
关键词：
carboplatin; gemcitabine; ovarian cancer; progression-free survival; response rate;
D O I：
10.1038/ncponc0795
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：340 / 341
页数：2
相关论文
共 50 条
  • [1] Which second-line treatment regimen should be used following relapse of platinum-sensitive ovarian cancer?
    Sergio Pecorelli
    Franco Odicino
    Nature Clinical Practice Oncology, 2007, 4 : 340 - 341
  • [2] Is there a "best" choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer?
    Cannistra, SA
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) : 1158 - 1160
  • [3] Second-line therapy for potentially platinum-sensitive recurrent ovarian cancer: What is optimal treatment?
    Markman, M
    GYNECOLOGIC ONCOLOGY, 2001, 81 (01) : 1 - 2
  • [4] Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study
    Ferrandina, G.
    Ludovisi, M.
    De Vincenzo, R.
    Salutari, V.
    Loruss, D.
    Colangelo, M.
    Prantera, T.
    Valerio, M. R.
    Scambia, G.
    ANNALS OF ONCOLOGY, 2007, 18 (08) : 1348 - 1353
  • [5] Maintenance Chemotherapy in Patients with Platinum-Sensitive Relapsed Epithelial Ovarian Cancer after Second-Line Chemotherapy
    Chen, Yen-Fu
    Hsu, Shih-Tien
    Hwang, Sheau-Feng
    Sun, Lou
    Liu, Chih-Ku
    Shih, Yu-Hsiang
    Lu, Ting-Fang
    Wang, Jun-Sing
    Lu, Chien-Hsing
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (02)
  • [6] MANAGEMENT OF FIRST RELAPSE IN PLATINUM-SENSITIVE OVARIAN CANCER
    Vieira, C.
    Teixeira, A.
    Vaz, A.
    Ferreira, A.
    Oliveira, J.
    Couto, R.
    Afonso, N.
    Sousa, S.
    Sousa, B.
    Pereira, D.
    ANNALS OF ONCOLOGY, 2008, 19 : 215 - 215
  • [7] Second-line treatment of first relapse recurrent ovarian cancer
    Chua, Terence C.
    Liauw, Winston
    Robertson, Gregory
    Morris, David L.
    AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY, 2010, 50 (05): : 465 - 471
  • [8] Paclitaxel and carboplatin as second-line therapy in women with platinum-sensitive ovarian carcinoma treated with platinum and paclitaxel as first-line therapy
    Eltabbakh, GH
    Yildirim, Z
    Adamowicz, R
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2004, 27 (01): : 46 - 50
  • [9] Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: A gynecologic oncology group study
    Rose, PG
    Blessing, JA
    Mayer, AR
    Homesley, HD
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) : 405 - 410
  • [10] A Phase 2 Evaluation of Irofulven as Second-line Treatment of Recurrent or Persistent Intermediately Platinum-Sensitive Ovarian or Primary Peritoneal Cancer A Gynecologic Oncology Group Trial
    Schilder, Russell J.
    Blessing, John A.
    Shahin, Mark S.
    Miller, David S.
    Tewari, Krishnansu Sujata
    Muller, Carolyn Y.
    Warshal, David P.
    McMeekin, Scott
    Rotmensch, Jacob
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2010, 20 (07) : 1137 - 1141
12345